Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

NCT06498973 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome

Interventions

DRUG: Azacitidine
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
OTHER: Questionnaire Administration
BIOLOGICAL: Tagraxofusp-erzs

Sponsor

City of Hope Medical Center

Collaborators

[object Object]